Skandinaviska Enskilda Banken AB publ Has $6.12 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Skandinaviska Enskilda Banken AB publ boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 47.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 62,079 shares of the medical equipment provider’s stock after acquiring an additional 19,996 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Zimmer Biomet were worth $6,115,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ZBH. Legacy Wealth Asset Management LLC lifted its stake in shares of Zimmer Biomet by 2.3% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after purchasing an additional 106 shares during the period. Global Retirement Partners LLC lifted its stake in Zimmer Biomet by 7.0% in the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 111 shares during the period. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the period. Generali Asset Management SPA SGR boosted its holdings in Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after buying an additional 122 shares during the last quarter. Finally, Brookstone Capital Management grew its position in shares of Zimmer Biomet by 1.3% during the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after buying an additional 123 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on ZBH shares. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. BTIG Research reiterated a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday, February 10th. William Blair began coverage on shares of Zimmer Biomet in a report on Friday. They issued a “market perform” rating for the company. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research note on Wednesday, November 5th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Stock Up 0.9%

NYSE:ZBH opened at $99.17 on Friday. The stock has a 50-day simple moving average of $90.50 and a 200 day simple moving average of $95.78. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a market cap of $19.65 billion, a PE ratio of 28.01, a PEG ratio of 2.01 and a beta of 0.62. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the prior year, the firm posted $2.31 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.